ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: QLT Inc. (QLTI) Report Updated: Sep 14, 2014 | Print This Page

Get more stock ratings by Louis Navellier

QLT Inc. (QLTI)

Rating: Buy Volatility: Moderate
Total Grade: B Industry: Biotechnology
Competitors: CBMG, ANAC, MDVN, GILD

Stock Analysis

Rating: Monthly View

A
B
C
D
F
September October November December January February March April May June July August

Rating: Weekly View

This Week: B down no change
Last Week: B same no change
Two Weeks Ago: B up no change
service keys

QLT Inc.© quotemedia

Company Profile

QLT Inc., a biotechnology company, engages in the development and commercialization of ocular products that address the unmet medical needs of patients and clinicians. It offers Visudyne that utilizes light-activated photodynamic therapy to treat the eye disease known as wet age related macular degeneration. Visudyne is also used for the treatment of subfoveal choroidal neovascularization secondary to pathologic myopia, severe near-sightedness, and presumed ocular histoplasmosis. The company’s developmental stage products include Latanoprost Punctal Plug Drug Delivery System, which is in Phase II clinical trial for the treatment of glaucoma and allergic conjunctivitis; and QLT091001, which is in Phase Ib clinical trial for the treatment of leber congenital amaurosis and retinitis pigmentosa. QLT Inc. markets its products in approximately 80 countries worldwide. The company was founded in 1981 and is headquartered in Vancouver, Canada.

Recent News: QLT Inc.